Viking Therapeutics (NASDAQ:VKTX) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Viking Therapeutics (NASDAQ:VKTX) released its earnings results on Wednesday. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01, MarketWatch Earnings reports.

Viking Therapeutics stock opened at $7.02 on Friday. The company’s fifty day simple moving average is $7.11 and its 200-day simple moving average is $6.41. Viking Therapeutics has a 12 month low of $3.26 and a 12 month high of $8.87.

Several analysts have recently weighed in on VKTX shares. BMO Capital Markets began coverage on Viking Therapeutics in a report on Thursday, June 4th. They issued an “outperform” rating and a $14.00 target price for the company. Oppenheimer reissued a “buy” rating and set a $12.00 target price on shares of Viking Therapeutics in a research note on Wednesday. B. Riley restated a “buy” rating and issued a $12.00 price target on shares of Viking Therapeutics in a report on Thursday. BidaskClub cut Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 15th. Finally, BTIG Research began coverage on Viking Therapeutics in a research report on Friday, May 1st. They issued a “buy” rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Viking Therapeutics presently has an average rating of “Buy” and a consensus price target of $14.78.

In related news, Director Matthew W. Foehr sold 13,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $7.35, for a total value of $95,550.00. Following the completion of the sale, the director now directly owns 26,250 shares in the company, valued at $192,937.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.70% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis.

Recommended Story: Why investors pay attention to retained earnings

Earnings History for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with's FREE daily email newsletter.